Globus Medical Inc. Class A (GMED)
NYSE: GMEDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GMED stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.90B
- P/E (TTM)
- 19.61
- Forward P/E
- 13.66
- EPS (TTM)
- $3.76
- Dividend yield
- None
- 52-week range
- 56.50 – 101.40
- Day range
- 73.26 – 76.66
- Volume / Avg
- 2.47M / 1.50M
- Beta
- —
- Shares outstanding
- 111.83M
- Next earnings
- Nov 5, 2026
52-week range
GMED stock today
On Oct 7, GMED ended the session at $73.75, shedding $2.68 (3.51%), versus the S&P 500's 0.22% decline. Shares are 27.3% below their 52-week high of $101.40, set on Jan 8, 2026 and 30.5% above the 52-week low of $56.50, in the middle of the past year's range. GMED is down 15.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 24.3%.
At 19.6x trailing earnings, Globus Medical trades below the peer-group median of 30.0x. Its forward P/E of 13.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Globus Medical's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Globus Medical
Company profileGlobus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Keith W. Pfeil
- Headquarters
- Audubon, PA
- Employees
- 6,000
- IPO year
- 2012
- Website
- globusmedical.com
Financial highlights
Full financialsIn fiscal 2025, Globus Medical generated $2.94 billion in revenue, up 16.7% from fiscal 2024, its 15th consecutive year of revenue growth. Net income was $537.9 million (+422.3% year over year), for a net margin of 18.3% versus a median of 13.0% in the prior 5 years. Gross margin was 67.4% (up from 58.9%) and operating margin 16.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.10M |
| Growth | +16.65% | +60.62% | +53.34% | +6.76% | +21.43% |
| Net income | $537.87M | $102.98M | $122.87M | $190.17M | $149.19M |
| EPS (diluted) | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$100.92+36.84%
- Strong buy 3
- Buy 7
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.20
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $1.10 vs —
GMED news
All GMED news- BDX Expands U.S. Manufacturing With $19B Healthcare InvestmentNasdaqBDX, WST, OPK, GMED
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesNasdaqVEEV, WST, GMED, VCYT
- Is This the Right Time to Add TMO Stock to Your Portfolio?NasdaqTMO, GMED, PAHC, VCYT
- Reasons to Retain Cardinal Health Stock in Your Portfolio for NowNasdaqCAH, MMSI, WST, GMED
- Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher ScientificNasdaqISRG, TMO, GMED
- Veeva's OpenData to Help Servier Build a Global AI Data FoundationNasdaqVEEV, WST, GMED, VCYT
- Inspire Medical Gains New CPT Codes for Hypoglossal Nerve StimulationNasdaqINSP, ISRG, WST, GMED
- 3 Medical Instruments Stocks Using GenAI to Navigate Industry WoesNasdaqISRG, TMO, GMED
Globus Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs GMED |
| PODDInsulet Corporation | 134.36 | -0.27% | $9.32B | vs GMED |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs GMED |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs GMED |
| MMEDMiniMed Group Inc. | 19.11 | -2.70% | $5.38B | vs GMED |
| STVNStevanato Group S.p.A. | 19.44 | -2.11% | $5.31B | vs GMED |
| TFXTeleflex Incorporated | 124.48 | -0.21% | $5.27B | vs GMED |
| SOLVSolventum Corporation | 85.88 | -1.33% | $14.62B | vs GMED |
Indexes, lists and sector
Globus Medical stock FAQ
What is Globus Medical's stock price today?
GMED last traded at $73.75 as of Oct 7, 4:00 PM EDT, down 3.51% on the day. Prices are delayed at least 15 minutes.
When is Globus Medical's next earnings date?
Globus Medical is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.20.
What is GMED's P/E ratio?
GMED trades at a trailing P/E ratio of 19.61 and a forward P/E of 13.66, compared with a median of 30.0 for its closest peers.
Who is Globus Medical's CEO?
Mr. Keith W. Pfeil is the chief executive officer of Globus Medical Inc. Class A, which has about 6,000 employees.
What is the GMED 52-week high?
The 52-week high for GMED is $101.40 and the 52-week low is $56.50. The stock is currently 27.3% below its high.